These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505 [TBL] [Abstract][Full Text] [Related]
10. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546 [TBL] [Abstract][Full Text] [Related]
11. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of an Italian series of sporadic GISTs. Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969 [TBL] [Abstract][Full Text] [Related]
14. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model. Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807 [TBL] [Abstract][Full Text] [Related]
15. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy. Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282 [TBL] [Abstract][Full Text] [Related]
17. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817 [TBL] [Abstract][Full Text] [Related]
18. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Jiao Y; Ou W; Meng F; Zhou H; Wang A Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244 [TBL] [Abstract][Full Text] [Related]
19. High KIT and PDGFRA are associated with shorter patients survival in gastroenteropancreatic neuroendocrine tumors, but mutations are a rare event. Knösel T; Chen Y; Altendorf-Hofmann A; Danielczok C; Freesmeyer M; Settmacher U; Wurst C; Schulz S; Yang LL; Petersen I J Cancer Res Clin Oncol; 2012 Mar; 138(3):397-403. PubMed ID: 22160160 [TBL] [Abstract][Full Text] [Related]
20. Association of epidermal growth factor receptor and mitogen-activated protein kinase with cystic neoplasms of the pancreas. Kuboki Y; Shiratori K; Hatori T; Fujita I; Kimijima A; Yamamoto M; Kobayashi M; Furukawa T Mod Pathol; 2010 Aug; 23(8):1127-35. PubMed ID: 20495538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]